Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Comparative Efficacy of Differential Trimethoprim-Sulfamethoxazole Dosing Regimen for Pneumocystis jirovecii Pneumonia Prophylaxis in Adults with Autoimmune Disease on PJP Infection Living in Ontario, Canada
FY 2023-24
Summary
Pneumocystis jirovecii pneumonia (PJP) is a rare and potentially deadly infection of the lungs affecting individuals with a reduced immune system, including those with autoimmune diseases. Trimethoprim sulfamethoxazole (TMP-SMX) is an antibiotic which can be taken at low doses to reduce the risk of having a PJP infection. While TMP-SMX reduces the risk of PJP, it can also lead to side effects, including lowering blood counts and increasing potassium levels. It is therefore important to use the dose of TMP-SMX that balances the benefits of reducing PJP infections with the fewest side effects. Unfortunately, the best dose of TMP-SMX is not known. There are three different doses that are recommended, but all three have never been compared to each other. I hope to be the first to compare between the three TMP-SMX doses to find the most effective and safe dose. It is difficult to use traditional studies, like randomized controlled trials, to make these comparisons, because PJP and drug side effects are rare. Instead, I will use health insurance data from people living in Ontario. I will include individuals 65 years or older with an autoimmune disease, who start taking TMP-SMX at one of three doses taken to prevent PJP. I will also measure baseline factors, like age, sex, medical history, and medications taken. Using advanced statistical techniques, I will adjust each group to make them equal on these baseline factors. I will then compare each regimen in its ability to reduce PJP, cause side effects, or lead to death. While PJP is a rare disease, there are millions of Canadians and individuals worldwide who are risk for it because of their reduced immune system. For this reason, finding the best TMP-SMX dose is important in improving their health.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
505854
Name
Arbiv Omri A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Comparative Efficacy of Differential Trimethoprim-Sulfamethoxazole Dosing Regimen for Pneumocystis jirovecii Pneumonia Prophylaxis in Adults with Autoimmune Disease on PJP Infection Living in Ontario, Canada
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmune Disease; Causal Inference; Drug Safety; Epidemiology; Immunosuppression; Pneumocystis Jirovecii Pneumonia; Real-World Studies; Rheumatologic Disease; Target Trial; Trimethoprim Sulfamethoxazole
Abstract
Pneumocystis jirovecii pneumonia (PJP) is a rare and potentially deadly infection of the lungs affecting individuals with a reduced immune system, including those with autoimmune diseases. Trimethoprim sulfamethoxazole (TMP-SMX) is an antibiotic which can be taken at low doses to reduce the risk of having a PJP infection. While TMP-SMX reduces the risk of PJP, it can also lead to side effects, including lowering blood counts and increasing potassium levels. It is therefore important to use the dose of TMP-SMX that balances the benefits of reducing PJP infections with the fewest side effects. Unfortunately, the best dose of TMP-SMX is not known. There are three different doses that are recommended, but all three have never been compared to each other. I hope to be the first to compare between the three TMP-SMX doses to find the most effective and safe dose. It is difficult to use traditional studies, like randomized controlled trials, to make these comparisons, because PJP and drug side effects are rare. Instead, I will use health insurance data from people living in Ontario. I will include individuals 65 years or older with an autoimmune disease, who start taking TMP-SMX at one of three doses taken to prevent PJP. I will also measure baseline factors, like age, sex, medical history, and medications taken. Using advanced statistical techniques, I will adjust each group to make them equal on these baseline factors. I will then compare each regimen in its ability to reduce PJP, cause side effects, or lead to death. While PJP is a rare disease, there are millions of Canadians and individuals worldwide who are risk for it because of their reduced immune system. For this reason, finding the best TMP-SMX dose is important in improving their health.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Arbiv, Omri A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~